The article by Grinda and colleagues in the December 2004 issue of the European Journal of Cardiothoracic Surgery regarding the experience of ventricular assist device (VAD) support on fulminant myocarditis (FM) [1] deserves our respect and we congratulate their excellent results.
From 1995 to 2001, we used extracorporeal membrane oxygenation (ECMO) in our institute as first-line mechanical support to treat 15 patients of FM with shock, including 5 under external cardio-pulmonary resuscitation (CPR) and 10 with high-degree atrio-ventricular block. Our results revealed 93.3% (14/15) in successful weaning rate and 73.3% (11/15) in discharge survival rate [2, 3] . The average ECMO support time was 129G50 h (127G83 h for the survivors). As compared with the article [1] and another study regarding ABIOMED use for FM [2] , ECMO group had lower morbidity rate than VAD group: mechanical related thrombo-embolism was 6.7% in ECMO group [3] and 40-27.3% in VAD group [1, 2] ; re-exploration for hemostasis was 20% in ECMO group [3] and 45.5% in VAD group [2] .
We would like to mention the following points for the mechanical support for FM. First, since FM tends to recover within 2 weeks [4] , ECMO is an appropriate option for this relatively short duration. ECMO is easier to wean off than VAD, and ECMO can be converted to VAD at any time if necessary. Secondly, biventricular involvement is common in FM (over 70% with right heart involvement as reported [4] ), therefore ECMO might be a suitable choice for FM in critical condition because the degree of right heart failure cannot be predicted accurately. Therefore, we agree the authors' protocol of using BiVAD. Third, the support duration to recovery was shorter in ECMO group than in VAD group (5.5G3.0 days in ECMO group [3] vs. 10.2G6.1 days for BiVAD group [1] and 10.0G5.3 days for ABIOMED group [2] ). This indicated that the theoretically incomplete decompression of left ventricle (LV) in ECMO group did not negatively influence the recovery of LV in FM. Fourth, daily troponin level was found as a good indicator for myocardial recovery in weaning of ECMO [3] , but it cannot be applied in VAD group.
The final solution of the best choice of mechanical support for FM still awaits further evidence-based studies.
I thank Dr Chen for his response, and I agree with him that the choice of the device is still debated [1] .
ECMO, or ECLS has many advantages (rapid peripheral technique of insertion, easy weaning), but many inconveniences, among them the incomplete unloading of the left ventricle.
As reported in the paper, we had a case of fulminant myocarditis in a 5-year-old, 20 kg, child. This patient had an ECMO previously inserted in another institution, with a mean flow of 1.8 l/min. But after 3 days, he presented with an intractable hemorrhage due to the level of anticoagulation and a severe hemolysis. The ETT showed spontaneous contrast in the left ventricle due to an incomplete left ventricular unloading and a severe liver dysfunction.
So we switched for a BIVAD (Medos HIA-VAD) and, with a flow of about 2 l, we obtained a complete unloading of the left cavities with a recovery on postoperative days 2 (FEVGZ30%). The patient was weaned from the BIVAD with a complete recovery (FEVG 60%) on post-operative day 7. We consider an efficient unloading of the left ventricle as a condition for rapid recovery, so our first choice is to assist fulminant myocarditis with BIVAD.
We read with interest the article published by Al-Hay and colleagues [1] . They report commendable results for the repair of partial AVSD with separate orifices over 21 years. The conclusion that the hypothesis that the 'cleft' or zone of apposition (ZoA) in the left atrioventricular (AV) valve should always be closed, is not proven. We think they go far too far in making their conclusion. Further, we must challenge some of the observations made in the light of our own observations and other's experiences of the management of the left AV valve in partial AVSD.
The design of their study cannot allow them to 'test a hypothesis'. The study is retrospective and observational, with no randomisation or predefined primary measures of outcome. The study groups they report are unequal and not contemporaneous. One could, just as reasonably, argue that any difference could have occurred by chance.
One may also reasonably conclude that those in whom the ZoA was left open were also those in whom the surgeon, at the time, felt had the least dysplastic and more morphologically robust valve. This is an intangible judgement that cannot be measured retrospectively, but may confound any subsequent conclusions drawn about the outcome.
Time and experience are showing that the ZoA between the bridging leaflets is not, and cannot, be managed as a simple commisure, and that the left AV valve falls morphologically short of the 'gold-standards' set by its mitral counterpart. We have observed, in morphological specimens in the archives of specimens held at Great Ormond Street, Pittsburgh and Boston museums (report in preparation [2] ), that the left AV valve in atrioventricular septal defects is deficient in terms of coaptation of the leaflets and sub-valvar cordal support, with the morphology of the left AV valve in the variants with separate orifices, the very subject of the report by Al-Hay and colleagues [1] , lying at the most extreme and adverse end of this sub-valvar deficiency.
